X4 Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	7yrs

Son yönetim güncellemeleri

Recent updates

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon

Dec 24

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors

Aug 12

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22

CEO

X4 Pharmaceuticals CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Craig	Executive Chair	less than a year	Veri yok	0.099% $ 334.5k
John Volpone	President & COO	less than a year	Veri yok	Veri yok
Richard Peters	Founder	no data	Veri yok	Veri yok
Renato Skerlj	Founder	no data	Veri yok	Veri yok
Keith Flaherty	Founder & Member of Corporate Advisory Board	no data	Veri yok	Veri yok
David Kirske	Chief Financial Officer	less than a year	Veri yok	Veri yok
Brian Bowersox	VP of Finance & Corporate Controller	6.5yrs	Veri yok	Veri yok

0.6yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: XFOR 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Craig	Executive Chair	less than a year	Veri yok	0.099% $ 334.5k
Keith Flaherty	Founder & Member of Corporate Advisory Board	9.9yrs	Veri yok	Veri yok
Michael Wyzga	Lead Independent Director	7.7yrs	US$136.80k	0.0046% $ 15.7k
Gary Bridger	Independent Director	7yrs	US$104.80k	0.0037% $ 12.5k
Michael Vasconcelles	Member of Corporate Advisory Board	9.9yrs	Veri yok	Veri yok
Murray Stewart	Director	7yrs	US$117.51k	0.0073% $ 24.8k
Francoise de Craecker	Independent Director	4.4yrs	US$104.80k	0.0037% $ 12.5k

7.0yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: XFOR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/13 12:50
Gün Sonu Hisse Fiyatı	2026/03/13 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, raporlarımızı nasıl kullanacağınız konusunda kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

X4 Pharmaceuticals, Inc. 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Leah Rush Cann	Brookline Capital Markets
Arlinda Lee	Canaccord Genuity
Michael Schmidt	Guggenheim Securities, LLC

X4 Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

X4 Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective August 12, 2025

X4 Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2025

CEO, President & Director notifies of intention to sell stock

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

Recent updates

X4 Pharmaceuticals Receives Positive Opinion from the Ema Chmp Recommending Approval of Mavorixafor in the Eu for Whim Syndrome

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon

Price target increased by 8.5% to US$8.00

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $135.0233 million.

X4 Pharmaceuticals Announces Restructuring of Business Operations

High number of new directors

Price target decreased by 46% to US$23.25

X4 Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective August 12, 2025

New major risk - Shareholder dilution

X4 Pharmaceuticals, Inc. announced that it expects to receive $59.999985 million in funding

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors

New major risk - Financial position

New major risk - Market cap size

X4 Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Grants Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data At the 30Th Annual Eha Congress

Consensus revenue estimates increase by 106%

Price target decreased by 43% to US$42.67

X4 Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2025

X4 Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 01, 2025

US Launch And EMA Approval Will Expand Global Reach

X4 Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

X4 Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 25, 2025

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

New major risk - Financial position

Price target decreased by 8.9% to US$3.68

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024

CEO, President & Director notifies of intention to sell stock

New minor risk - Market cap size

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

New major risk - Revenue and earnings growth

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates increase by 12%

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

Price target increased by 8.7% to US$3.55

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Price target increased by 13% to US$3.65

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 8.9% to US$3.20

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target increased by 7.5% to US$3.76

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Price target decreased by 9.5% to US$4.07

Price target decreased by 12% to US$4.21

Consensus revenue estimates fall by 11%

Price target decreased to US$5.08

Price target increased to US$5.90

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals: Upcoming Catalysts

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended